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Abstract
Background
The National Lung Screening Trial (NLST) results indicate that computed tomography (CT)
lung cancer screening for current and former smokers with three annual screens can be
cost-effective in a trial setting. However, the cost-effectiveness in a population-based setting
with >3 screening rounds is uncertain. Therefore, the objective of this study was to estimate
the cost-effectiveness of lung cancer screening in a population-based setting in Ontario,
Canada, and evaluate the effects of screening eligibility criteria.
Methods and Findings
This study used microsimulation modeling informed by various data sources, including the
Ontario Health Insurance Plan (OHIP), Ontario Cancer Registry, smoking behavior surveys,
and the NLST. Persons, born between 1940 and 1969, were examined from a third-party
health care payer perspective across a lifetime horizon. Starting in 2015, 576 CT screening
scenarios were examined, varying by age to start and end screening, smoking eligibility cri-
teria, and screening interval. Among the examined outcome measures were lung cancer
deaths averted, life-years gained, percentage ever screened, costs (in 2015 Canadian dol-
lars), and overdiagnosis. The results of the base-case analysis indicated that annual screen-
ing was more cost-effective than biennial screening. Scenarios with eligibility criteria that
required as few as 20 pack-years were dominated by scenarios that required higher num-
bers of accumulated pack-years. In general, scenarios that applied stringent smoking eligi-
bility criteria (i.e., requiring higher levels of accumulated smoking exposure) were more
PLOS Medicine | DOI:10.1371/journal.pmed.1002225 February 7, 2017 1 / 20
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: ten Haaf K, Tammema¨gi MC, Bondy SJ,
van der Aalst CM, Gu S, McGregor SE, et al. (2017)
Performance and Cost-Effectiveness of Computed
Tomography Lung Cancer Screening Scenarios in
a Population-Based Setting: A Microsimulation
Modeling Analysis in Ontario, Canada. PLoS Med
14(2): e1002225. doi:10.1371/journal.
pmed.1002225
Academic Editor: Steven D. Shapiro, University of
Pittsburgh, UNITED STATES
Received: May 29, 2016
Accepted: December 14, 2016
Published: February 7, 2017
Copyright: © 2017 ten Haaf et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data for this study
were obtained from several sources. Information
for data access is provided in the supplemental file
S6 Text.
Funding: This study was supported by the Institute
for Clinical Evaluative Sciences (ICES), which is
funded by an annual grant from the Ontario
Ministry of Health and Long-Term Care (MOHLTC),
Cancer Care Ontario, and the Ontario Institute for
cost-effective than scenarios with less stringent smoking eligibility criteria, with modest dif-
ferences in life-years gained. Annual screening between ages 55–75 for persons who
smoked40 pack-years and who currently smoke or quit10 y ago yielded an incremental
cost-effectiveness ratio of $41,136 Canadian dollars ($33,825 in May 1, 2015, United States
dollars) per life-year gained (compared to annual screening between ages 60–75 for per-
sons who smoked40 pack-years and who currently smoke or quit10 y ago), which was
considered optimal at a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114
May 1, 2015, US dollars). If 50% lower or higher attributable costs were assumed, the incre-
mental cost-effectiveness ratio of this scenario was estimated to be $38,240 ($31,444 May
1, 2015, US dollars) or $48,525 ($39,901 May 1, 2015, US dollars), respectively. If 50%
lower or higher costs for CT examinations were assumed, the incremental cost-effective-
ness ratio of this scenario was estimated to be $28,630 ($23,542 May 1, 2015, US dollars)
or $73,507 ($60,443 May 1, 2015, US dollars), respectively.
This scenario would screen 9.56% (499,261 individuals) of the total population (ever- and
never-smokers) at least once, which would require 4,788,523 CT examinations, and reduce
lung cancer mortality in the total population by 9.05% (preventing 13,108 lung cancer deaths),
while 12.53% of screen-detected cancers would be overdiagnosed (4,282 overdiagnosed
cases). Sensitivity analyses indicated that the overall results were most sensitive to variations
in CT examination costs. Quality of life was not incorporated in the analyses, and assumptions
for follow-up procedures were based on data from the NLST, which may not be generalizable
to a population-based setting.
Conclusions
Lung cancer screening with stringent smoking eligibility criteria can be cost-effective in a
population-based setting.
Author Summary
Why Was This Study Done?
• In the US, lung cancer screening is recommended for current and former smokers who
have quit within the past 15 y, aged 55 through 80 who smoked at least 30 pack-years;
other countries are investigating the feasibility of implementing lung cancer screening
policies.
• Despite lung cancer screening being recommended by a number of organizations, the
cost-effectiveness of lung cancer screening is uncertain; concerns have been raised on
the potential costs of implementing lung cancer screening.
• Past studies that evaluated the cost-effectiveness of lung cancer screening yielded incon-
clusive results. However, these studies considered limited numbers of screening policies,
providing limited information on how different screening policy characteristics affect
the cost-effectiveness of lung cancer screening.
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What Did the Researchers Do and Find?
• This study investigated how different screening policy characteristics, such as screening
starting and stopping ages, screening interval, and different smoking history eligibility
criteria, influence the performance and cost-effectiveness of lung cancer screening.
• A microsimulation model was used to analyze 576 different lung cancer screening poli-
cies for persons born between 1940 and 1969 in Ontario, Canada.
• The study found that requiring stringent smoking history eligibility criteria (i.e., requir-
ing higher levels of accumulated smoking exposure) was more cost-effective than less
stringent smoking history eligibility criteria.
What Do These Findings Mean?
• Limiting screening to individuals with substantial (past) smoking histories may allow
lung cancer screening to be implemented in a cost-effective manner.
• In contrast to initial expectations, annual screening is suggested to be more cost-effec-
tive than biennial screening.
Introduction
The National Lung Screening Trial (NLST) showed that screening with low-dose computed
tomography (CT) can reduce lung cancer mortality [1]. Although the sensitivity of CT screen-
ing in the NLST was reported to be over 90% across the three screening rounds, the reported
specificity ranged from 73.4% in the first round to 83.9% in the third round [1]. Overall, 23.3%
of the CT screens in the NLST were false positive, which often required additional follow-up
CT examinations and, infrequently, invasive procedures (such as a biopsy, bronchoscopy, or
thoracotomy) to determine the malignancy of one or more suspicious pulmonary nodules
detected by CT screening [1]. Lung cancer screening with three annual screens, as performed
in the NLST, was reported to be cost-effective by US standards, yielding estimated cost-effec-
tiveness ratios of US$52,000 per life-year gained and US$81,000 per quality-adjusted life-year
gained [2,3]. However, although the cost-effectiveness of lung cancer screening in a popula-
tion-based setting has been examined previously, it has not been examined extensively [4–9].
To determine the cost-effectiveness of implementing cancer screening programs, microsi-
mulation modeling is invaluable [10,11]. The United States Preventive Services Task Force
(USPSTF) recommended lung cancer screening for current and former smokers who have
quit within the past 15 y, aged 55 through 80 who smoked at least 30 pack-years [12]. This rec-
ommendation was in part based on a comparative modeling study using microsimulation
models, as modeling allows one to extrapolate the results of randomized clinical trials and pro-
vide information on the long-term benefits and harms for screening programs with different
designs and populations than those considered in clinical trials [13]. However, although the
modeling study that informed the USPSTF provides an understanding of the trade-offs
between the benefits and harms of different screening scenarios, it did not formally consider
their cost-effectiveness [13].
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In Ontario, Canada, lung cancer is responsible for the largest proportion of cancer deaths
(49.9 per 100,000 individuals) in the population of 13.8 million individuals, despite falling
smoking rates [15,28,55,56]. The implementation of a lung cancer screening program, in addi-
tion to continued efforts in primary prevention of smoking, could reduce lung cancer mortal-
ity. However, concerns have been raised about whether and how such a program can be
implemented in a cost-effective manner [14,16]. Previous studies on the cost-effectiveness of
population-based lung cancer screening have yielded inconclusive results, ranging from US
$18,452–US$66,480 per life-year gained and US$27,756–US$243,077 per quality-adjusted life-
year gained [4–9]. However, many of these studies reported the average cost-effectiveness
ratios (ACER, the ratio of differences in costs to differences in health effects compared to no
screening) of the investigated screening scenarios as the incremental cost-effectiveness ratios
(ICER, the ratio of incremental costs to incremental health effects of a screening policy relative
to its next best alternative), which can give misleading cost-effectiveness estimates [17].
Furthermore, these studies considered limited numbers of screening scenarios, providing
little information on the effects of screening eligibility criteria, and may have had insufficient
numbers of comparator scenarios to yield correct ICERs [18]. The aim of this study was to
investigate the benefits (such as lung cancer mortality reduction and the number of life-years
gained), harms (such as the number of false-positive results and occurrence of overdiagnosis),
and cost-effectiveness of many different lung cancer screening scenarios for the population of
Ontario, overcoming some of the limitations of previous studies.
Materials and Methods
Ethics Statement
This study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre
on behalf of the Institute for Clinical Evaluative Sciences (ICES). Individual consent for access
to de-identified data was not required.
MISCAN-Lung
The MIcrosimulation SCreening ANalysis (MISCAN) Lung model was used for this analysis.
Other versions of the MISCAN model have been used to investigate the cost-effectiveness of
screening programs for breast, colorectal, cervical, and prostate cancers [19–22]. The MIS-
CAN-Lung model used in these analyses was previously calibrated to individual-level data from
the NLST and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, from which
information on the preclinical duration of lung cancer and the effectiveness of CT screening
were derived [23,24]. MISCAN-Lung was one of the models used to inform the USPSTF on
their recommendations for lung cancer screening [13]. The structure of the model and its
underlying assumptions have been described previously and are detailed in S1 Text; the charac-
teristics of the investigated population are described in the following section and in S2 and S3
Texts [23,24].
In brief, MISCAN-Lung simulates life histories for each individual in the considered popu-
lation from birth until death in the presence and absence of screening. For each individual, a
smoking history is generated based on data on the investigated population. A person’s smok-
ing history influences the probability of developing preclinical lung cancer as well as the proba-
bility of dying from other causes. The model considers four histological types of lung cancer:
adenocarcinoma/large cell carcinoma/bronchioloalveolar carcinoma, squamous cell carci-
noma, other non-small cell carcinoma, and small cell carcinoma. Once preclinical lung cancer
has developed, it is assumed to progress through stages IA to IV. During each stage, the cancer
may be detected due to symptoms, after which the person is assumed to undergo treatment
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with associated treatment costs. Lung cancer survival after clinical diagnosis is dependent on
the histology and stage of the cancer and the person’s gender. If the screening component is
activated, preclinical lung cancers may be detected by screening (at the expense of screening-
related costs), which may alter a person’s life history: detection by screening allows treatment
at an earlier stage, which may cure the individual, allowing him or her to resume a normal
(lung cancer-free) life history. The probability that an individual is cured due to early detection
differs by the stage at detection. Screening may also result in serious harms, such as overdiag-
nosis (the detection of a disease that would never have been detected if screening had not
occurred), which may lead to unnecessary (invasive) follow-up procedures, treatments, and
anxiety. The effects of screening are derived through utilizing information on the preclinical
duration of lung cancer, the screen-detectability of lung cancer, and relevant information on
the examined population (such as smoking behavior and other-cause mortality corrected for
smoking history) to model the life histories of individuals in the presence and absence of
screening [25]. Through comparing the life histories in the presence of screening with the cor-
responding life histories in the absence of screening, MISCAN-Lung can estimate the effective-
ness and costs of screening scenarios.
Simulated Population
Three different birth cohorts were investigated: 1940–1949 (ages 66–75 in 2015), 1950–1959
(ages 56–65 in 2015), and 1960–1969 (ages 46–55 in 2015). These cohorts represent appro-
ximately 5.2 million individuals in 2016 in the age range for which the USPSTF currently re-
commends lung cancer screening [12,26]. Birth tables for each cohort were derived from
information from Statistics Canada and the Ontario Ministry of Finance [26,27]. Ontario-spe-
cific data on smoking behavior were used to model smoking initiation and cessation probabili-
ties and the average number of cigarettes smoked per day (divided into five categories) by age
and gender for each cohort [28–32]. Life tables by birth year and gender were extracted from
the Canadian Human Mortality Database and adjusted for smoking behavior and lung cancer
mortality, as shown graphically for persons born in 1955 in S2 Text Figs C–F [32]. Further
information on the methods used to model smoking behavior and adjustment of the life tables
for smoking behavior is provided in S2 Text. The age- and gender-specific lung cancer inci-
dence, histology proportions, and stage proportions estimated by MISCAN-Lung were com-
pared to observed data from the Ontario Cancer Registry from 2007–2009, in which screening
did not occur, and are detailed in S3 Text [33].
Screening Scenarios
In total, 576 potential screening scenarios were evaluated. The evaluated scenarios considered
different combinations of the following characteristics: age to start screening; age to stop
screening; screening interval; and screening eligibility regarding cumulative smoking exposure,
years since smoking cessation (for former smokers, defined as individuals who have quit smok-
ing permanently), and whether or not former smokers were excluded from further screening
after they reach a maximum number of years since cessation (Table 1). Two types of cumulative
smoking criteria, of which one is used at a time in an evaluated scenario, were distinguished:
the first type was based on the cumulative number of pack-years, used in the NLST (“NLST-
like”) [1]; the second type of cumulative smoking criteria was based on the criteria used in the
Dutch-Belgian lung cancer screening trial (NELSON), which evaluated a person’s smoking
duration and average number of cigarettes per day separately (“NELSON-like”) [34]. Of the 576
screening scenarios, 216 screening scenarios considered “NLST-like” criteria (including the cri-
teria currently recommended by the USPSTF), whereas 360 screening scenarios considered
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“NELSON-like” criteria. Perfect attendance to screening was assumed for the base-case investi-
gation. Estimations regarding screen-related procedures such as false-positive results (defined
as receiving a positive screening test result when lung cancer is not found after diagnostic work-
up), follow-up CT examinations, screen-related biopsies/bronchoscopies, and non-lung cancer-
related surgeries were derived from individual-level data from the CT-arm of the NLST and are
described in S4 Text. Limited information on morbidity and mortality has been reported from
randomized controlled trials. In a subgroup analysis of NELSON participants, 1% of partici-
pants were found to have incidental findings that required additional work-up procedures or
treatment [35]. However, no information on morbidity or mortality was reported. In the NLST,
0.06% of the positive screening tests in the low-dose CT group that did not result in a diagnosis
of lung cancer were associated with a major complication after an invasive procedure [1]. Over-
all, six individuals with a positive screening test in the low-dose CT group that did not result in
a diagnosis of lung cancer died within 60 d after an invasive diagnostic procedure (0.04%), but
it was unknown whether these deaths were caused by complications of the diagnostic proce-
dures [1]. Thus, given the low occurrence of invasive procedures along with a low frequency of
major complications, the occurrence of morbidity or death related to screen-related follow-up
procedures is expected to be minor.
Costs
The analyses were conducted from a third-party health care payer perspective. Fully allocated
costs for lung cancer treatment were estimated by stage, age, and gender from the date of diag-
nosis until the date of death or last known date of follow-up (by person-month) through data
from the Ontario Health Insurance Plan (OHIP), the Canadian Institute for Health Informa-
tion (CIHI), the Ontario Drug Benefit Plan database, the Ontario Chronic Care database, the
Ontario Home Care database, and the Ontario New Drug Funding Program. These datasets
Table 1. Characteristics of the lung cancer screening scenarios evaluated by the MISCAN-Lung
model.
Scenario characteristic Considered values
Age to start screening 50, 55, 60
Age to stop screening 75, 80
Screening interval Annual, Biennial
Minimum cumulative smoking criteria*
Pack-years (NLST-like scenarios) 20 pack-years, 30 pack-years, 40 pack-years
Minimum number of years smoked and minimum
number of cigarettes per day during years smoked
(NELSON-like scenarios)
25 y of smoking at least 10 cigarettes per day or
30 y of smoking at least 5 cigarettes per day
20 y of smoking at least 15 cigarettes per day or
25 y of smoking at least 10 cigarettes per day
25 y of smoking at least 15 cigarettes per day or
30 y of smoking at least 10 cigarettes per day
30 y of smoking at least 15 cigarettes per day or
35 y of smoking at least 10 cigarettes per day
Additional smoking-related criteria
Maximum number of years since smoking cessation to
be eligible for first screening invitation
10, 15, 20
Exclusion from further screening after reaching the
maximum number of years since smoking cessation
No, Yes
*Either pack-years or minimum number of years smoked and minimum number of cigarettes per day during
years smoked are used in an evaluated screening scenario.
doi:10.1371/journal.pmed.1002225.t001
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were linked using unique encoded identifiers and were analyzed at the ICES. Controls without
a lung cancer diagnosis from the Registered Persons Database (a roster of all OHIP beneficia-
ries) were matched to 12,713 staged cases of lung cancer from the Ontario Cancer Registry (10
controls matched per case), based on age, sex, median household income, and census tract on
the date of diagnosis of the case. Fully allocated costs were estimated similarly for controls.
The fully allocated costs of controls were subtracted from the fully allocated costs for cases in
order to obtain the attributable costs of lung cancer care by phase of care (initial, continuing,
and terminal care) [36]. By incorporating the fully allocated costs of lung cancer care by phase
of care, it is taken into account that individuals whose lung cancer death is averted will on
average incur higher costs over their remaining lifetime. In MISCAN-Lung, the attributable
costs for stage I were assumed for the modeled stages IA and IB, whereas the attributable costs
of stage III were assumed for the modeled stages IIIA and IIIB.
Each person’s eligibility for lung cancer screening was assumed to be free of misclassifica-
tion error. Therefore, upon entering the eligible age range for the considered screening scenar-
ios, each ever-smoking individual was assumed to receive an invitation for a lung cancer risk
assessment. It was assumed that half of all ever-smokers would accept this invitation; half of
the individuals who participated in the risk assessment were assumed to request a consultation
with a primary care physician about their risk. Costs for screening-related events were deter-
mined using 2013 data from OHIP and CIHI. The costs for screening invitations and fixed
costs related to the screening program, such as costs for the screening registry, program infra-
structure, communications, and advertising, were derived from those incurred in the recent
establishment of the colorectal screening program administered by Cancer Care Ontario. The
costs for risk assessments were estimated assuming that screening program staff trained in
health communication would administer the assessments. Fixed costs were counted up to the
year in which the last individuals in the cohorts are eligible for screening (2045 for screening
scenarios that end at age 75, 2050 for screening scenarios that end at age 80).
All costs were expressed in Canadian dollars (using May 2013 levels as a base) and were
adjusted to reflect the May 2015 prices for health care services using the Ontario Consumer
Price Index derived from Statistics Canada [37]. A lifetime time horizon for the costs and
effects of screening was applied to each simulated person. Annual discount rates of 3% were
applied to both costs and effects, using 2015 as the reference year [38]. The estimated attribut-
able costs of lung cancer care by phase of care and the estimated costs related to the screening
program are presented in Tables 2 and 3, respectively. To reflect the uncertainty in these cost
estimates, sensitivity analyses were performed, which varied the costs by 50%, as described in a
later section of this manuscript. Although cost-effectiveness thresholds have been proposed in
the past, there is no official cost-effectiveness threshold employed in the Canadian health care
system [37]. Therefore, a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 in
May 1, 2015, US dollars) per life-year gained was chosen, similar to previous Canadian cost-
effectiveness studies [39,40].
Benefits, Harms, and Cost-Effectiveness of Screening Scenarios
For each screening scenario, the number of lung cancer deaths prevented, life-years gained,
proportion of individuals ever screened, number of CT examinations, screen-related biopsies/
bronchoscopies, false-positive screens, non-lung cancer-related surgeries, overdiagnoses, and
costs were compared with a situation in which screening does not occur, from 2015 onward.
Screening scenarios that were more costly and less effective (i.e., fewer life-years gained) than
other scenarios were ruled out as non-efficient by simple dominance. Scenarios that were
more costly and less effective than a combination of other scenarios were also ruled out as
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non-efficient by extended dominance. The remaining screening scenarios constitute the fron-
tier of efficient screening scenarios, i.e., the efficient frontier. For each efficient screening sce-
nario, the ICER was determined, calculated as the incremental net costs per incremental life-
year gained compared to the previous efficient screening scenario.
Sensitivity Analyses
A number of sensitivity analyses were performed to investigate which groups of cost estimates
and attendance assumptions have the greatest influence on the cost-effectiveness estimates by
varying the costs for CT examinations by 50% compared with the base-case analyses, varying
the attributable costs of lung cancer care by phase of care by 50% compared with the base-case
analyses, and imperfect attendance rates for screening: low attendance (33% overall compli-
ance rate), average attendance (55% overall compliance rate), and high attendance (64% over-
all compliance rate). Sensitivity analyses were performed for all 576 scenarios to investigate the
effects of variations in assumptions on the composition of the efficient frontier.
Table 2. Attributable costs (in Canadian dollars) estimates used in the MISCAN-Lung model. Costs were estimated per phase of lung cancer care per
person-year of treatment by gender, age, and stage of disease for Ontario, Canada.
Initial care phase Men Women
Age group/Lung cancer stage Stage I Stage II Stage
III
Stage
IV
Stage I Stage II Stage
III
Stage
IV
Younger than 60 $30,272 $41,283 $49,676 $45,374 $27,172 $42,441 $44,576 $43,170
60–69 $29,440 $37,959 $45,788 $38,073 $27,454 $37,773 $47,589 $39,411
70–79 $31,603 $39,444 $41,832 $32,659 $27,178 $43,439 $42,779 $32,493
Older than 80 $27,391 $24,669 $32,569 $29,886 $27,284 $32,394 $29,414 $29,035
Continuing care phase Men Women
Age group/Lung cancer stage Stage I Stage II Stage
III
Stage
IV
Stage I Stage II Stage
III
Stage
IV
Younger than 60 $5,617 $8,451 $10,458 $18,683 $4,859 $6,777 $8,626 $13,716
60–69 $3,371 $4,276 $7,270 $5,004 $5,559 $7,424 $9,214 $12,062
70–79 $3,019 $1,938 $5,011 $5,616 $2,124 $6,447 $6,999 $5,656
Older than 80 $4,785 $1,938 $1,689 $5,616 $2,022 $6,447 $7,475 $10,882
Terminal care phase (death due to causes other than lung
cancer)
Men Women
Age group/Lung cancer stage Stage I Stage II Stage
III
Stage
IV
Stage I Stage II Stage
III
Stage
IV
Younger than 60 $17,174 $21,061 $17,775 $23,884 $13,741 $2,332 $4,689 $14,284
60–69 $13,596 $10,586 $13,690 $17,548 $13,741 $20,660 $5,591 $6,869
70–79 $15,887 $15,887 $9,858 $9,032 $15,875 $10,999 $12,917 $4,300
Older than 80 $15,887 $15,887 $9,368 $8,243 $21,554 $28,188 $2,217 $6,030
Terminal care phase of lung cancer (lung cancer death) Men Women
Age group/Lung cancer stage Stage I Stage II Stage III Stage
IV
Stage I Stage II Stage
III
Stage
IV
Younger than 60 $72,167 $70,323 $84,041 $98,611 $51,164 $71,024 $89,322 $94,906
60–69 $73,085 $82,296 $84,828 $95,000 $51,164 $81,256 $79,563 $87,113
70–79 $68,187 $91,114 $77,067 $97,320 $68,844 $73,176 $77,424 $89,056
Older than 80 $55,413 $141,182 $69,807 $78,002 $68,844 $59,590 $83,353 $73,453
Costs were estimated from a third-party health care payer perspective by matching lung cancer patients in the Ontario Cancer Registry to persons
registered in the OHIP, free of lung cancer, by age, sex, median household income, and census tract on the date of diagnosis of the case. Additionally, data
from the CIHI, the Ontario Drug Benefit Plan database, the Ontario Chronic Care database, the Ontario Home Care database, and the Ontario New Drug
Funding Program were used.
doi:10.1371/journal.pmed.1002225.t002
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Results
Screening Scenarios on the Efficient Frontier
The net discounted costs and life-years gained (from 2015 onwards) for each scenario were
used to determine the screening scenarios on the efficient frontier, i.e., the scenarios that pro-
vide the highest number of life-years gained for their costs, in the base-case analysis, as shown
in Figs 1 and 2. The scenarios that are on the efficient frontier are described in Table 4 and
shown in Fig 2. A complete overview of the net discounted costs and life-years gained of all
investigated screening scenarios is presented in S1 Appendix Figs A–H. All outcomes were
reported per 100,000 individuals alive in 2015.
All scenarios on the efficient frontier consist of annual screening (Table 4), while biennial
screening is dominated. Assuming a cost-effectiveness threshold of $50,000 Canadian dollars
($41,114 May 1, 2015, US dollars) per life-year gained as acceptable for the Canadian health
care system, Scenario #2 was considered optimal: current and former smokers (who quit 10
y ago) who smoked40 pack-years would be screened annually between ages 55–75, yielding
Table 3. Costs (in Canadian dollars) of screening-related events and fixed program costs used in the
MISCAN-Lung model.
Cost estimates related to screening invitations
Description Unit costs
Invitation to assess lung cancer risk $5
Lung cancer risk assessment $32
Visit with primary care physician with regards to lung cancer risk assessment $67
Initial and repeat screening invitations $3
Cost estimates for screening- and follow-up–related procedures
Description Unit costs
Screening CT examination $430
Follow-up CT examination $430
Visit with primary care physician with regards to the results of a follow-up chest CT $41
Percutaneous cytologic analysis/bronchoscopy/biopsy $1,355
Non-lung cancer surgery for potentially benign disease $11,844
Fixed program cost estimates per year (per 100,000 individuals alive in 2015)*
Description Yearly
costs
First year $823,321
Second year up to the year in which the last individuals in the cohorts are eligible for
screening (2045 for screening scenarios that end at age 75, 2050 for screening scenarios
that end at age 80)
$411,660
Costs for screening-related events were estimated using 2013 data from the OHIP and the CIHI. The costs
for program invitations and fixed costs related to the screening program, such as costs for the screening
registry, program infrastructure, communications, and advertising, were derived from those incurred in the
recent establishment of ColonCancerCheck, the colorectal screening program administered by Cancer Care
Ontario. The costs for lung cancer risk assessments were estimated assuming that screening program staff
trained in health communication would administer the assessments.
*The fixed costs per 100,000 individuals alive in 2015 consist of one-time, first year only startup costs for
Information Technology infrastructure ($411,661 Canadian dollars), annual maintenance costs for Information
Technology infrastructure ($61,749 Canadian dollars), annual costs for maintaining main screening centers
($144,081 Canadian dollars), annual costs for communications and advertising ($102,915 Canadian dollars),
and annual costs for provincial program management and evaluation ($102,915 Canadian dollars).
doi:10.1371/journal.pmed.1002225.t003
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an ICER of $41,136 Canadian dollars ($33,825 May 1, 2015, US dollars) per life-year gained. If
50% lower or higher attributable costs were assumed, the ICER of this scenario was estimated
to be $38,240 ($31,444 May 1, 2015, US dollars) or $48,525 ($39,901 May 1, 2015, US dollars),
respectively. If 50% lower or higher costs for CT examinations were assumed, the ICER of this
scenario was estimated to be $28,630 ($23,542 May 1, 2015, US dollars) or $73,507 ($60,443
May 1, 2015, US dollars), respectively.
Fig 1. The cost-effectiveness of all 576 investigated lung cancer screening scenarios in the base-case analysis. Results are presented per 100,000
individuals alive in 2015 and are discounted by 3% annually. Scenarios on the efficient frontier are described in Table 4.
doi:10.1371/journal.pmed.1002225.g001
Fig 2. The incremental cost-effectiveness of the lung cancer screening scenarios on the efficient frontier. Results are presented per 100,000
individuals alive in 2015 and are discounted by 3% annually. Scenarios on the efficient frontier are described in Table 4.
doi:10.1371/journal.pmed.1002225.g002
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Table 4. Cost-effectiveness estimates for lung cancer screening scenarios on the efficient frontier.
Scenario # Starting
age of
screening
Stopping
age of
screening
Screening
interval
Maximum
number of
years since
cessation
Cumulative
smoking
criteria
Exclusion from
further
screening
invitations
after reaching
the maximum
number of
years since
cessation
Discounted
costs compared
to no screening
(in Canadian
dollars) per
100,000
Discounted
life-years
gained per
100,000
Costs (in
Canadian
dollars) per life-
year gained
(discounted)/
ACER compared
to no screening
ICER
compared to
the previous
efficient
scenario
#1 60 75 Annual 10 40 pack-years
(NLST-like)
Yes $49,768,886 1,276 $39,006 -
#2 55 75 Annual 10 40 pack-years
(NLST-like)
Yes $58,549,938 1,489 $39,311 $41,136
#3 55 75 Annual 10 30 pack-years
(NLST-like)
Yes $72,978,421 1,746 $41,801 $56,262
#4 55 80 Annual 10 30 pack-years
(NLST-like)
Yes $78,858,485 1,834 $43,001 $66,802
#5 55 75 Annual 15 30 pack-years
(NLST-like)
Yes $87,658,495 1,965 $44,600 $66,885
#6 55 80 Annual 15 30 pack-years
(NLST-like)
Yes $95,859,980 2,088 $45,916 $67,065
#7 55 80 Annual 20 30 y of smoking
at least 15
cigarettes per
day or 35 y of
smoking at least
10 cigarettes per
day (NELSON-
like)
Yes $114,462,449 2,359 $48,530 $68,675
#8 55 80 Annual 20 30 y of smoking
at least 15
cigarettes per
day or 35 y of
smoking at least
10 cigarettes per
day (NELSON-
like)
No $124,978,314 2,500 $49,998 $74,557
#9 50 80 Annual 20 30 y of smoking
at least 15
cigarettes per
day or 35 y of
smoking at least
10 cigarettes per
day (NELSON-
like)
No $131,929,978 2,592 $50,901 $75,370
#10 50 80 Annual 20 25 y of smoking
at least 15
cigarettes per
day or 30 y of
smoking at least
10 cigarettes per
day (NELSON-
like)
No $162,994,771 2,877 $56,661 $109,083
#11 50 80 Annual 20 25 y of smoking
at least 10
cigarettes per
day or 30 y of
smoking at least
5 cigarettes per
day (NELSON-
like)
No $206,703,139 3,214 $64,304 $129,394
Results are per 100,000 individuals alive at the start of 2015. An annual discount rate of 3% annually was applied to costs and life-years gained.
doi:10.1371/journal.pmed.1002225.t004
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In addition, the benefits and harms of all scenarios on the efficient frontier were examined
(Table 5). Scenario #2 would reduce lung cancer mortality in the overall population (which
includes non-eligible individuals) by 9.05%, preventing 251 lung cancer deaths and gaining
2,531 life-years (undiscounted) over the lifetime of the program (i.e., on average, 10.08 life-
years would be gained for each lung cancer death prevented). However, in Scenario #2, 9.56%
of the overall population would receive at least one screen, requiring 91,692 CT screens and
follow-up examinations. This scenario would lead to 14,729 false-positive screens and 163 sur-
geries for potentially benign disease (in persons in whom lung cancer is not detected) and 350
biopsies/bronchoscopies (in persons in whom lung cancer is not detected). Ultimately, 12.53%
of all screen-detected cancers would be overdiagnosed, leading to 82 overdiagnosed cases.
Based on the estimated number of individuals in the examined cohorts in 2016, Scenario #2 is
estimated to screen 499,261 individuals at least once, require 4,788,523 CT examinations, and
prevent 13,108 lung cancer deaths, while 4,282 cases of lung cancer would be overdiagnosed
[26,27]. The average annual non-discounted costs compared to no screening would be approx-
imately $1,400,000 Canadian dollars ($1,151,178 May 1, 2015, US dollars) over the considered
time period; however, the annual costs are higher in the first years compared to later years, due
to diminishing numbers of individuals meeting the eligibility criteria. For example, the average
non-discounted costs compared to no screening are approximately $5,000,000 Canadian dol-
lars ($4,111,350 May 1, 2015, US dollars) for 2015–2020 compared with approximately
$1,600,000 Canadian dollars ($1,315,632 May 1, 2015, US dollars) in 2030–2035.
Effects of Screening Scenario Characteristics on Cost-Effectiveness
Scenarios with older starting ages have lower costs compared with scenarios that start at youn-
ger ages but also yield a smaller number of life-years gained (S1 Appendix Fig A). Raising the
Table 5. Overview of selected benefits and harms (per 100,000 individuals alive at the start of 2015) of the screening scenarios on the efficient fron-
tier (effect estimates are not discounted).
Scenario #* Percentage
of the total
population
ever
screened
CT screens
and follow-up
examinations
(per 100,000)
Lung
cancer
mortality
reduction in
the total
population
(%)
Lung
cancer
deaths
prevented†
(per
100,000)
Life-
years
gained
(per
100,000)
Average
number
of life-
years
gained
per lung
cancer
death
averted
Percentage of
screen-
detected
cancers that
are
overdiagnosed
Number of
overdiagnosed
lung cancers
(per 100,000)‡
False-
positive
screens
(per
100,000)
Number of
non-lung
cancer
surgeries
due to
screening§
(per
100,000)
Biopsies
due to
screening§
(per
100,000)
#1 8.74% 73,248 8.24% 229 2,170 9.48 13.06% 80 11,937 132 283
#2 9.56% 91,692 9.05% 251 2,531 10.08 12.53% 82 14,729 163 350
#3 13.03% 125,320 10.50% 292 2,993 10.25 12.31% 93 20,145 223 479
#4 13.04% 135,410 11.71% 325 3,159 9.72 14.43% 127 21,575 239 514
#5 15.41% 161,159 11.93% 331 3,388 10.24 12.34% 106 25,698 285 612
#6 15.42% 177,014 13.58% 377 3,624 9.61 14.68% 150 27,947 311 667
#7 16.06% 225,062 15.71% 436 4,129 9.47 14.89% 176 34,933 390 838
#8 16.06% 255,207 17.32% 481 4,422 9.19 15.48% 203 39,228 438 943
#9 16.19% 270,354 17.59% 489 4,577 9.36 15.36% 204 41,414 463 997
#10 19.99% 355,448 19.51% 542 5,142 9.49 15.15% 221 54,259 607 1,308
#11 26.13% 473,383 21.92% 609 5,774 9.48 15.14% 248 72,221 809 1,742
* Scenario details are provided in Table 4.
† Number of lung cancer deaths per 100,000 without screening: 2,777.
‡ Number of lung cancer cases per 100,000 without screening: 3,522.
§ For persons in whom lung cancer was not detected by screening.
doi:10.1371/journal.pmed.1002225.t005
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age to stop screening from 75 to 80 increases the costs and the number of life-years gained, but
differences are modest (S1 Appendix Fig B). A comparison of scenarios by smoking eligibility
criteria indicates that there is little difference between using NLST-like or NELSON-like smok-
ing eligibility criteria (S1 Appendix Fig C).
S1 Appendix Figs D–G demonstrate the importance of cumulative smoking criteria on
cost-effectiveness. Each increase in the cumulative smoking requirement for enrollment sub-
stantially decreases the costs while modestly decreasing the number of life-years gained in
both NLST-like (S1 Appendix Fig D) and NELSON-like (S1 Appendix Fig E) screening scenar-
ios. In other words, scenarios that apply stringent cumulative smoking eligibility criteria are
closer to the efficient frontier than those that apply less restrictive cumulative smoking eligibil-
ity criteria. In general, scenarios that require only 20 pack-years are dominated by scenarios
that apply more stringent (higher) pack-year criteria.
Increasing the maximum number of years since smoking cessation (S1 Appendix Fig F)
and not excluding individuals from further screening once they reach the maximum number
of years since cessation (S1 Appendix Fig G) both increase the costs and the numbers of life-
years gained. However, the effects of these criteria are less pronounced than those related to
cumulative smoking requirements.
S1 Appendix Fig H shows the effects of annual screening compared with biennial screening.
Although biennial screening scenarios have substantially lower costs compared with annual
screening scenarios, the life-years gained are also substantially lower. S1 Appendix Fig H dem-
onstrates that annual screening scenarios dominate biennial screening scenarios.
Sensitivity Analyses
Altering assumptions about attendance rates, CT examination costs, and attributable costs
impacted the scenarios on the efficient frontier in the base-case analysis to varying degrees. Fig
3 provides an overview of the scenarios on the efficient frontier in the base-case analysis along
with the discounted life-years gained and costs for these scenarios in the sensitivity analyses.
Altering assumptions also impacted the composition of the efficient frontier, as shown in
S5 Text. When the attendance rates were varied, lower attendance rates were observed to shift
scenarios with less restrictive criteria, especially with regards to smoking behavior, on the effi-
cient frontier (S5 Text Tables A–C). This may be due to the fixed costs of the screening scenarios,
which are independent of the number of screened individuals; at lower levels of participation
these costs have a greater influence on the cost-effectiveness than the costs of CT examinations.
When the attributable costs were varied, it was observed that halving the attributable costs
had little effect on the scenarios on the efficient frontier (S5 Text Table D). When the attribut-
able costs were doubled, it was observed that scenarios with less restrictive criteria, especially
with regards to smoking cessation, were shifted on the efficient frontier (S5 Text Table E).
When the costs of CT examinations were varied, it was observed that halving the costs of
CT examinations also shifted scenarios with less restrictive criteria, in particular with regards
to smoking cessation, on the efficient frontier (S5 Text Table F). Doubling the costs of CT
examinations had the greatest effect of all sensitivity analyses; the scenarios with the most
restrictive criteria with regards to age and smoking were shifted on the efficient frontier and
the least costly scenarios on this efficient frontier favored biennial screening (S5 Text Table G).
Scenario #2 was on the efficient frontier across all sensitivity analyses, with the exception
of assuming the lowest attendance rates (S5 Text Table H). In contrast, although Scenario #5
closely resembles the eligibility criteria that were used in the NLST, it was not on the efficient
frontier in any of the sensitivity analyses.
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Discussion
This simulation study indicates that lung cancer screening can be cost-effective in a popula-
tion-based setting when eligibility is restricted to high-risk groups. In contrast, utilizing loose
eligibility criteria yields nonoptimal and potentially cost-ineffective scenarios, as the cost-effec-
tiveness of lung cancer screening is highly dependent on scenario characteristics, primarily the
smoking eligibility criteria. Scenarios that utilize stringent smoking eligibility criteria are more
cost-effective than scenarios that utilize less restrictive smoking eligibility criteria due to a
focus on individuals at higher risk of developing lung cancer. This greatly reduces the number
of screening examinations while still screening those at highest risk. Thus, the level of lung
cancer risk at which an individual is eligible for lung cancer screening should be considered
before implementing lung cancer screening policies. Future research should investigate the
cost-effectiveness of lung cancer screening selection based on accurate lung cancer risk predic-
tion models using suitable risk thresholds [41–43].
The results of this study suggest that the greater reduction in lung cancer mortality and
number of life-years gained by annual screening outweigh the costs of the additional number
of CT examinations compared with biennial screening, which has previously been suggested
to be equally or more cost-effective than annual screening [14,44]. However, previous studies
indicated that lung cancer may be more difficult to detect in stage IA with biennial screening
[24]. As survival in stage IA is considerably higher compared with other stages, the potential
for mortality reduction and life-years gained is higher for annual screening compared to
Fig 3. The incremental cost-effectiveness of the lung cancer screening scenarios on the efficient frontier and their corresponding cost-
effectiveness throughout different sensitivity analyses. Results are presented per 100,000 individuals alive in 2015 and are discounted by 3% annually.
The relative ranking of the scenarios is consistent across sensitivity analyses (i.e., if a scenario is more costly and gains more life-years than another
scenario in the base-case analysis, this is also the case in all sensitivity analyses).
doi:10.1371/journal.pmed.1002225.g003
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biennial screening [45]. This is supported by the modeling study that informed the USPSTF,
which showed that annual screening provides substantial benefits over biennial screening at
modest diminishing returns [13].
Previous studies that examined the cost-effectiveness of lung cancer screening only consid-
ered limited numbers of screening scenarios, which provided limited information on the
effects of scenario characteristics [4–8]. The results of this study suggest that scenario charac-
teristics, especially smoking eligibility criteria and screening interval, influence the cost-effec-
tiveness of a scenario and suggest that a large variety of scenarios should be considered. In
addition, considering a wide variety of screening scenarios provides sufficient comparator
scenarios to yield appropriate ICERs [18]. Previous studies often reported the ACERs of the
investigated screening scenarios as the ICERs, which can give misleading cost-effectiveness
estimates [17]. This study provides both the ACERs and the ICERs of the scenarios on the effi-
cient frontier, in contrast to previous studies that generally did not report an efficient frontier
[4–8]. The robustness of the scenarios on the efficient frontier in this study is demonstrated by
the sensitivity analyses of all 576 scenarios. This study incorporates both allocated costs for all
screening-related procedures and attributable costs for various stages of lung cancer care, which
were derived from government data in a province with universal health care, which allows for
more comprehensive and accurate cost estimates compared with other studies. Furthermore, this
study incorporates detailed information on smoking behavior and smoking-related mortality in
contrast to previous studies. Finally, although the majority of previous studies only reported the
number of life-years gained, this study reports a variety of benefits (such as lung cancer mortality
reduction and the number of life-years gained) and harms (such as the number of false-positive
results and the occurrence of overdiagnosis).
This study has some limitations; for example, quality of life was not incorporated in the
analyses. There may be some differences in quality of life between annual and biennial screen-
ing, as more frequent screening will increase the impact of screening and follow-up–related
effects on quality of life. However, results from the NELSON trial indicate that although CT
lung cancer screening has a minor impact on quality of life in the short term, the long-term
effects are negligible [46,47]. In addition, utility estimates for lung cancer care are highly vari-
able [48].
Another limitation is that assumptions for follow-up procedures were based on data from
the NLST, which may not be generalizable to a population-based setting, as screening algo-
rithms with reduced false-positive rates are being investigated [1,49–51]. By reducing the false-
positive rates, the number of unnecessary follow-up CTs and invasive diagnostic procedures
may be reduced as well, further improving the cost-effectiveness of lung cancer screening.
Finally, although fully allocated costs for lung cancer care and observed costs for the admin-
istration of a cancer screening program were incorporated in the analyses, the government of
Ontario only reimburses the physician costs of a CT examination. However, capital invest-
ments would be required to acquire the CT scanners necessary to implement a lung cancer
screening program, which could influence the costs per CT examination. Conversely, the
increased CT capacity could potentially lead to discounts on the costs per CT examination.
This study used a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 May 1,
2015, US dollars) per life-year gained, similar to previous Canadian cost-effectiveness studies
[39]. However, the acceptable ratio between costs and effects differs between countries. For
example, although a cost-effectiveness threshold of US$100,000 per quality-adjusted life-year
has been proposed for the US, the United Kingdom’s National Institute for Health and Care
Excellence uses a £20,000–£30,000 ($30,274–$45,411 May 1, 2015, US Dollars) threshold to
determine cost-effectiveness [3,52,53]. Thus, the optimal screening scenario depends in part
on the chosen cost-effectiveness threshold: if a cost-effectiveness threshold of $60,000
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Canadian dollars ($49,336 May 1, 2015, US dollars) per life-year gained was chosen, Scenario
#3 (annual screening for persons aged 55–75 who smoked at least 30 pack-years and currently
smoke or quit smoking less than 10 y ago) would have been considered the optimal scenario.
However, the ICER of Scenario #2 (annual screening for persons aged 55–75 who smoked at
least 40 pack-years and currently smoke or quit smoking less than 10 y ago) remained below
the proposed cost-effectiveness threshold of $50,000 Canadian dollars per life-year gained in 5
out of 7 sensitivity analyses (71.4%) with a range of $28,630–$73,507 Canadian dollars per life-
year gained. This suggests that both the dominance and cost-effectiveness of Scenario #2 are
robust across various sensitivity analyses.
Although our results suggest that a uniform biennial screening interval is dominated by a
uniform annual screening interval, recent studies suggest it may be possible to identify individ-
uals for whom biennial screening intervals could be recommended. NLST participants with a
negative prevalence screen had a substantially lower risk of developing lung cancer compared
to individuals with a positive prevalence screen [54]. Results from the NELSON trial suggest
that the 2-y probability of developing lung cancer after a CT screen varied substantially by
nodule size and volume doubling time [51]. Future research should evaluate whether the inter-
val between screens can be varied based on previous screening results and what impact this
has on cost-effectiveness. In addition, precision medicine could improve the treatment of
selected individuals, and biomarkers might help to distinguish between indolent nodules and
aggressive nodules requiring rapid diagnosis and treatment. The impacts of these future devel-
opments need to be assessed.
In conclusion, this study indicates that lung cancer screening can be cost-effective in a pop-
ulation-based setting if stringent smoking eligibility criteria are applied. Annual screening sce-
narios are more cost-effective than biennial screening scenarios.
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